Market News AIOpen the app

Citigroup says to buy Arrowhead Pharmaceuticals and keeps its price target at $105.

OpinionRead the original at moomoo.com
Good for ARWR

Citigroup kept its bullish rating and $105 target for Arrowhead. Its continued positive view supports the company, though the report gives no new business results.

ARWR · Arrowhead Pharmaceuticals, Inc.

AI read · Good for ARWR

The AI's read

The report adds no new sales, trial, or financial results. Its value is the analyst's continued confidence in Arrowhead's prospects, so it offers a modest positive sign but no fresh proof of business progress.

Get alerts for ARWR

Follow Arrowhead Pharmaceuticals, Inc. (ARWR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ARWR
Free on the App Store and Google Play, or on the web.